EMA — authorised 27 November 2011
- Application: EMEA/H/C/002312
- Marketing authorisation holder: Gilead Sciences International Ltd
- Local brand name: Eviplera
- Indication: Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.
- Status: approved